CLINICAL AND POPULATION STUDIES

Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19

Jeffrey S. Berger, Dennis Kunichoff, Samrachana Adhikari, Tania Ahuja, Nancy Amoroso, Yindalon Aphinyanaphongs, Meng Cao, Ronald Goldenberg, Alexander Hindenburg, James Horowitz, Sam Parnia, Christopher Petrilli, Harmony Reynolds, Emma Simon, James Slater, Shadi Yaghi, Eugene Yuriditsky, Judith Hochman, Leora I. Horwitz

OBJECTIVE: To determine the prevalence of D-dimer elevation in coronavirus disease 2019 (COVID-19) hospitalization, trajectory of D-dimer levels during hospitalization, and its association with clinical outcomes.

APPROACH AND RESULTS: Consecutive adults admitted to a large New York City hospital system with a positive polymerase chain reaction test for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) between March 1, 2020 and April 8, 2020 were identified. Elevated D-dimer was defined by the laboratory-specific upper limit of normal (>230 ng/mL). Outcomes included critical illness (intensive care, mechanical ventilation, discharge to hospice, or death), thrombotic events, acute kidney injury, and death during admission. Among 2377 adults hospitalized with COVID-19 and ≥1 D-dimer measurement, 1823 (76%) had elevated D-dimer at presentation. Patients with elevated presenting baseline D-dimer were more likely than those with normal D-dimer to have critical illness (43.9% versus 18.5%; adjusted odds ratio, 2.4 [95% CI, 1.9–3.1]; P<0.001), any thrombotic event (19.4% versus 10.2%; adjusted odds ratio, 1.9 [95% CI, 1.4–2.6]; P<0.001), acute kidney injury (42.4% versus 19.0%; adjusted odds ratio, 2.4 [95% CI, 1.9–3.1]; P<0.001), and death (29.9% versus 10.8%; adjusted odds ratio, 2.1 [95% CI, 1.6–2.9]; P<0.001). Rates of adverse events increased with the magnitude of D-dimer elevation; individuals with presenting D-dimer >2000 ng/mL had the highest risk of critical illness (66%), thrombotic event (37.8%), acute kidney injury (58.3%), and death (47%).

CONCLUSIONS: Abnormal D-dimer was frequently observed at admission with COVID-19 and was associated with higher incidence of critical illness, thrombotic events, acute kidney injury, and death. The optimal management of patients with elevated D-dimer in COVID-19 requires further study.

GRAPHIC ABSTRACT: A graphic abstract is available for this article.

Key Words: acute kidney injury • critical illness • epidemiology • mortality • thrombosis

The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) coronavirus (coronavirus disease 2019 [COVID-19]) infection is a global pandemic, with >6200000 cases and 375000 deaths confirmed as of June 1, 2020, and at least 376000 confirmed cases in New York State alone. The clinical spectrum of COVID-19 infection is broad, encompassing asymptomatic infection, mild upper respiratory tract illness, respiratory failure, and death. Recent reports highlight an alarming incidence of acute kidney injury and both arterial and venous thrombotic events. A recent report by our group found the overall incidence of thrombosis in hospitalized patients with COVID-19 to be 16%, which after multivariable adjustment was associated with a 82% increased hazard of all-cause mortality (P<0.001). The most common pattern of abnormal coagulation observed in patients hospitalized with COVID-19 is characterized by elevations in fibrinogen and D-dimer levels. D-dimer is the principal breakdown fragment of fibrin and is used as a biomarker of fibrin formation and degradation. Numerous studies have shown that D-dimer is a valuable marker of activation of coagulation and fibrinolysis.

Correspondence to: Jeffrey S. Berger, MD, MS, FAHA, FACC, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, 530 First Ave, Skirball 9R, New York, NY 10016. Email jeffreyberger@nyumc.org

The Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/ATVBAHA.120.314872.

For Sources of Funding and Disclosures, see page 2546.

© 2020 American Heart Association, Inc.

Arterioscler Thromb Vasc Biol is available at www.ahajournals.org/journal/atvb

Arterioscler Thromb Vasc Biol. 2020;40:2539–2547. DOI: 10.1161/ATVBAHA.120.314872 October 2020 2539
individuals have low levels of circulating D-dimer, whereas elevated levels are found in conditions associated with thrombosis. D-dimer has been extensively investigated for the diagnosis, monitoring, and treatment of venous thromboembolism (VTE) for which it is used routinely. D-dimer levels are also elevated in conditions of chronic inflammation, such as active malignancy, rheumatoid arthritis, sickle cell disease, and asthma. In the setting of COVID-19, D-dimer has been reported to be higher in subjects who are critically ill or those who expire. However, the incidence of outcomes across different D-dimer levels both at clinical presentation and during the course of hospitalization are not well characterized. In addition, the trajectory of D-dimer in subjects with COVID-19 remains unexplored.

The study was approved by the New York University (NYU) Study Setting

Patient level data from this project are not available to the public.

Study Setting

The study was approved by the New York University (NYU) Grossman School of Medicine Institutional Review Board and performed with a waiver of informed consent. We identified consecutive adults aged ≥18 years with a positive real-time polymerase chain reaction COVID-19 test between March 1, 2020 and April 08, 2020 who were admitted to NYU Langone Health, a multihospital health system in New York City. Follow-up was complete through May 13, 2020.

Data Collection

Data were obtained from the electronic health record (Epic Systems, Verona, WI), which is an integrated electronic health record including all inpatient and outpatient visits in the health system.

D-dimer was measured in patients hospitalized with a positive polymerase chain reaction test for COVID-19 who were eligible for this retrospective, observational study if ≥1 D-dimer was measured during hospital admission. At all 4 NYU Langone Health inpatient facilities, routine D-dimer surveillance for individuals with suspected or confirmed diagnoses of COVID-19 was included in COVID-19-specific admission order sets in the electronic heath record at the time of hospital admission starting March 25. At all NYU Langone Health sites, D-dimer assay was measured using the Hemosil D-dimer HS 500 on an automated coagulation analyzer (ACL TOP, Instrumentation Laboratory). The initial D-dimer and all D-dimers measured during hospital admission were recorded for all eligible patients. The upper limit of normal for the D-dimer assay is 230 ng/mL. Subjects were categorized into normal (D-dimer <230 ng/mL) and elevated (D-dimer ≥230 ng/mL) categories. We conducted sensitivity analyses using different D-Dimer categories: <230 ng/mL (normal), 230 to 500 ng/mL, 500 to 2000 ng/mL, and >2000 ng/mL.

Study Variables

Demographic variables included age, sex, race/ethnicity (defined as non-Hispanic White, non-Hispanic Black, Hispanic, Asian, multiracial/other, and unknown), smoking status, and body mass index. Preexisting comorbidities included hypertension, hyperlipidemia, coronary artery disease, heart failure, diabetes mellitus, chronic kidney disease, and atrial fibrillation. Prior medication information included statins, β-blockers, ACE (angiotensin-converting enzyme) inhibitor (ACE-I) or angiotensin receptor blocker, and oral anticoagulants.

Clinical Outcomes

All-cause, in-hospital mortality was recorded for all patients. Critical illness was defined by a composite of treatment in an intensive care unit, need for mechanical ventilation, discharge to hospice, or death. Thrombotic events, as determined by the treating physician, were defined as a composite of deep venous thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke, or systemic embolism. Acute kidney injury was defined according to the acute kidney injury network guidelines as an absolute increase of 0.3 mg/dL or more or a relative increase of 50% or more from baseline to peak creatinine. The most recent outpatient creatinine in the past 6 months was

| Nonstandard Abbreviations and Acronyms | Highlights |
|---------------------------------------|-----------|
| ACE-I | angiotensin-converting enzyme-inhibitor |
| COVID-19 | coronavirus disease 2019 |
| IQR | interquartile range |
| PROTECT | Prophylactic versus Therapeutic Anticoagulation Trial |
| VTE | venous thromboembolism |

- In this cohort study of 2377 consecutive patients with confirmed coronavirus disease 2019 (COVID-19), D-dimer was elevated in 76% of patients at hospital presentation.
- D-dimer was independently associated with incidence of critical illness, thrombosis, acute kidney injury, and all-cause mortality.
- In patients hospitalized with COVID-19, level of D-dimer may be used to identify gradient of risk.
used as baseline. When no creatinine was available, admission creatinine was used.

**Statistical Analyses**

Continuous variables are shown using mean (SD) and median (interquartile range [IQR]) and compared using the nonparametric Mann-Whitney *U* test for all non-normally distributed data. Categorical variables are reported as frequency rates and percentages and compared by χ² tests. The longitudinal trajectory of the mean D-dimer per day of hospitalization for patients in each outcome category was visualized using the fitted values from the loess regression for each end point separately. Logistic regression models were generated to estimate the odds of the study end points, adjusted for demographics, clinical comorbidities, vital signs at presentation, and baseline medications. Covariates in the multivariable models included age, sex, race, body mass index, tobacco use, hypertension, hyperlipidemia, chronic kidney disease, prior heart failure, atrial fibrillation, coronary artery disease, cancer, prior prescriptions for ACE or angiotensin receptor blockers, angicoagulants, statins, and β-blockers, and initial laboratory results for lymphocyte count, ferritin, and C-reactive protein. The c-index was reported as a measure of the model fitness. Statistical analyses were performed using statistical software R (R Foundation for Statistical Computing, Vienna, Austria), with packages forestplot, ggplot2, and base R. Statistical tests are 2-sided, and *P* values <0.05 were considered to be statistically significant.

**RESULTS**

Of 2782 consecutive hospitalized subjects testing positive for SARS-CoV-2 between March 1, 2020 and April 8, 2020, a total of 405 (14.6%) subjects had no D-dimer drawn and were excluded (Figure I in the Data Supplement). Of the remaining 2377, the median age was 64 (IQR, 52–74), and 39% were female. Overall, the initial median D-dimer was 387 (25th–75th percentile, 237–713), and 1823 (76%) presented with an elevated D-dimer (>230 ng/mL). The median peak D-dimer was 767 (25th–75th percentile, 328–3372), and 2049 (86%) had an elevated D-dimer >230 ng/mL at some point during the course of hospitalization.

Compared with patients with a normal baseline D-dimer, patients with an elevated baseline D-dimer were older (median age, 65 [IQR=54–77] versus 58 [46–68] years; *P*<0.001) and had a lower body mass index (median [IQR], 28.8 [25.2–33.1] versus 29.9 [26.2–34.4]; *P*<0.001; Table 1). Comorbidities were more frequent among patients with an elevated D-dimer, including hypertension (63.5% versus 57.7%, *P*=0.016), hyperlipidemia (44.2% versus 38.0%, *P*=0.012), coronary artery disease (23.4% versus 16.0%, *P*=0.001), and chronic kidney disease (23.0% versus 14.0%, *P*<0.001). Cardiovascular medications were also more common in the elevated baseline D-dimer group. In terms of laboratory findings, patients with elevated baseline D-dimer had higher levels of median creatinine (1.0 [IQR=0.8–1.5] versus 0.9 [0.8–1.1], *P*<0.001), white blood cell count (4.0 [2.0–10] versus 3.0 [1.0–11], *P*<0.001), C-reactive protein (125 [71–187] versus 75.1 [37–124], *P*<0.001), platelet count (203 [157–265] versus 190 [155–242], *P*<0.001), ferritin (833 [402–1621] versus 543 [293–983], *P*<0.001), and lower levels of lymphocytes (0.8 [0.6–1.2] versus 0.9 [0.7–1.3], *P*<0.001; Table 1).

**Clinical Outcomes**

During the course of hospitalization, 899 (37.8%) had critical illness, 620 (26.1%) required mechanical ventilation, 410 (17.2%) had a thrombotic event, and 871 (36.8%) had acute kidney injury. Compared with those with normal baseline D-dimer, individuals with elevated D-dimer were more likely to become critically ill (43.9% versus 18.5%; *P*<0.001) and more often required invasive mechanical ventilation (29.9% versus 13.9%, *P*<0.001). Thrombotic events (19.4% versus 10.2%, *P*<0.001) and acute kidney injury (42.4% versus 19.0%, *P*<0.001) were more common in the elevated D-dimer group (Figure 1; Table I in the Data Supplement). After adjustment for demographics, comorbidities, prior medications, and baseline laboratory values, elevated D-dimer was associated with higher odds of critical illness (OR, 2.4 [95% CI, 1.9–3.1], *P*<0.001), thrombotic events (OR, 1.9 [95% CI, 1.4–2.6]; *P*<0.001), and acute kidney injury (OR, 2.4 [95% CI, 1.9–3.1]; *P*<0.001). Rates of critical illness, thrombosis, and acute kidney injury increased with the level of D-dimer (Figure II in the Data Supplement), which remained significant after multivariable adjustment (Table 2). Individuals with a presenting D-dimer ≥2000 ng/mL had the highest risk of critical illness (65.4%), thrombotic event (36.9%), and acute kidney injury (58.7%). All adjusted models had c-indices >0.75, indicating reasonable discriminatory ability of the models. D-dimer trajectory by critical illness, thrombosis, and acute kidney injury are presented in Figure 2A through 2C. D-dimer levels generally peaked ≈5 days into hospitalization.

**D-Dimer and All-Cause Mortality**

Among the 2377 hospitalized patients with COVID-19, 608 (25.6%) died or were discharged to hospice, 1652 patients (69.5%) were discharged, and the rest (117 [4.9%]) remained hospitalized. Unadjusted mortality was higher among patients with versus without elevated baseline D-dimer (548 [29.9%] versus 60 [10.8%]; OR, 3.5 [95% CI, 2.7–4.7]; *P*<0.001) as shown in Figure 3. The multivariable adjusted odds ratio showed a significantly higher odds of death in patients with elevated D-dimer than in those without (OR, 2.1 [95% CI, 1.6–2.9]; *P*<0.001). Mortality increased in association with the level of D-dimer (Figure 3). The association between elevated D-dimer and mortality was consistent across multiple subgroups, including age, sex, body mass index,
hypertension, atrial fibrillation, and kidney disease (Figure III in the Data Supplement). Individuals with a presenting D-dimer >2000 ng/mL had the highest risk of all-cause mortality (48.3%). D-dimer trajectory by all-cause mortality is presented in Figure 2D.

### Peak D-Dimer and Clinical Outcomes

Individuals with the highest peak D-dimer concentrations had the highest risk of critical illness, thrombotic events, acute kidney injury, and mortality (Figure IV

| Table 1. Patient Characteristics According to Baseline D-Dimer |
|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | Normal <230 ng/mL | Elevated ≥230 ng/mL | P Value |
| Age, y; median (IQR) | 58 (46–68) | 65 (54–76) | <0.001 |
| Age ≥75 y | 76 (13.7%) | 498 (27.3%) | <0.001 |
| Female | 211 (37.8%) | 671 (36.7%) | 0.672 |
| Race/ethnicity |                |                | 0.001 |
| White NH | 190 (34.1%) | 733 (40.1%) | |
| Black NH | 60 (10.8%) | 278 (15.2%) | |
| Hispanic | 183 (32.8%) | 478 (26.2%) | |
| Asian | 42 (7.5%) | 128 (7.0%) | |
| Other/multiracial | 56 (10.0%) | 144 (7.9%) | |
| Unknown | 27 (4.8%) | 67 (3.7%) | |
| Tobacco use (%) |                |                | 0.008 |
| Current smoker | 30 (5.4%) | 90 (4.9%) | |
| Former smoker | 86 (15.4%) | 391 (21.4%) | |
| Body mass index, kg/m²; median (IQR) | 29.9 (26.2–34.4) | 28.8 (25.2–33.1) | <0.001 |
| Clinical history on admissions (%) |                |                | 0.016 |
| Hypertension | 322 (57.7%) | 1160 (63.46%) | |
| Hyperlipidemia | 212 (37.9%) | 807 (44.15%) | 0.012 |
| Coronary artery disease | 89 (15.9%) | 427 (23.36%) | <0.001 |
| Heart failure | 50 (8.96%) | 254 (13.89%) | 0.003 |
| Diabetes mellitus | 220 (39.4%) | 700 (38.29%) | 0.666 |
| Cancer | 46 (8.24%) | 195 (10.67%) | 0.113 |
| Chronic kidney disease | 78 (13.98%) | 421 (23.03%) | <0.001 |
| Atrial fibrillation | 46 (8.26%) | 154 (8.46%) | 0.949 |
| Medications before admission |                |                | 0.259 |
| Statin | 85 (15.2%) | 242 (13.2%) | |
| β blocker | 61 (11.0%) | 233 (12.8%) | 0.277 |
| ACE-I or ARB | 83 (14.9%) | 303 (16.7%) | 0.361 |
| Oral anticoagulant | 41 (7.4%) | 160 (8.8%) | |
| Temperature at presentation median (IQR), °C | 37.6 (37.1–38.3) | 37.4 (36.9–38.2) | 0.004 |
| Oxygen saturation at presentation median (IQR, %) | 94 (92–96) | 93 (89–96) | <0.001 |
| Initial laboratory markers (median [IQR]) |                |                | 0.001 |
| Creatinine, mg/dL | 0.9 (0.8–1.1) | 1.0 (0.8–1.5) | |
| White blood cell, x10^9/L | 3 (1–11) | 4 (2–10) | 0.038 |
| Lymphocyte, x10^9/L | 0.9 (0.7–1.3) | 0.8 (0.6–1.2) | <0.001 |
| C-reactive protein, mg/L | 75.1 (37–124) | 125 (71–187) | <0.001 |
| Hemoglobin, g/dL | 13.5 (12.4–14.6) | 13.1 (11.8–14.3) | <0.001 |
| Platelet count, x10^9/L | 190 (155–242) | 203 (157–265) | 0.004 |
| Ferritin, ng/mL | 543 (293–983) | 833 (402–1621) | <0.001 |
| D-dimer, ng/mL | 195 (149–204) | 490.5 (332–928) | <0.001 |

ACE-I indicates angiotensin-converting enzyme-inhibitor; ARB, angiotensin receptor blocker; IQR, interquartile range; and NH, Non-Hispanic.
in the Data Supplement). Among 301 (12.7%) individuals with a peak D-dimer >10,000 ng/mL, critical illness was present in 86.1%, thrombotic events in 39.5%, and acute kidney injury in 80.8%, and in-hospital mortality was 60.5% (Table II in the Data Supplement).

**DISCUSSION**

Among 2377 adults hospitalized with COVID-19 at 4 hospitals within a large health system in New York City, 1823 (76%) had evidence of elevated D-dimer above the laboratory-specific upper limit of normal at hospital admission.
presentation and 2049 (86%) had an elevated D-dimer at any point during the hospitalization before discharge. Outcomes of patients with elevated D-dimer at the time of admission were particularly poor, with 45% critically ill, 20% with thrombosis, and 43% with acute kidney injury. D-dimer level was independently associated with these outcomes after multivariable adjustment for demographics, clinical characteristics, and other biomarkers that we have previously shown are associated with adverse outcomes. In contrast, individuals without an elevated D-dimer at presentation were more likely to be discharged without developing a critical illness. This is the first report to (1) demonstrate a robust association between elevated D-dimer, measured at admission and during hospitalization, and critical illness and mortality after covariate adjustment, (2) provide associations

| Table 2. Unadjusted and Adjusted OR for Patient Outcomes |
|----------------------------------------------------------|
|                                                        |
|                                                        |
| Acute kidney injury                                      |
|                                                        |
| Normal D-dimer (<230 ng/mL)                              | 1.0  | 1.0  |
| Elevated D-dimer (≥230 ng/mL)                            | 3.08 (2.45–3.89) | <0.001  | 2.44 (1.89–3.14) | <0.001  |
| D-dimer level, ng/mL                                     |
| 230–500                                                  | 2.23 (1.73–2.87) | <0.001  | 1.95 (1.49–2.56) | <0.001  |
| >500 and ≤2000                                          | 3.71 (2.85–4.83) | <0.001  | 2.82 (2.1–3.78) | <0.001  |
| >2000                                                   | 5.99 (4.33–8.3) | <0.001  | 4.5 (3.14–6.45) | <0.001  |
| Critical illness                                         |
|                                                        |
| Normal D-dimer (<230 ng/mL)                              | 1.0  | 1.0  |
| Elevated D-dimer (≥230 ng/mL)                            | 3.54 (2.6–4.48) | <0.001  | 2.44 (1.89–3.14) | <0.001  |
| D-dimer level, ng/mL                                     |
| 230–500                                                  | 2.32 (1.8–2.99) | <0.001  | 1.75 (1.34–2.3) | <0.001  |
| >500 and ≤2000                                          | 4.48 (3.43–5.86) | <0.001  | 3.07 (2.3–4.11) | <0.001  |
| >2000                                                   | 8.58 (6.15–11.98) | <0.001  | 5.6 (3.91–8.03) | <0.001  |
| Thrombosis†                                              |
|                                                        |
| Normal D-dimer (<230 ng/mL)                              | 1.0  | 1.0  |
| Elevated D-dimer (≥230 ng/mL)                            | 2.09 (1.55–2.82) | <0.001  | 1.88 (1.37–2.58) | <0.001  |
| D-dimer level, ng/mL                                     |
| 230–500                                                  | 1.38 (0.99–1.92) | 0.06  | 1.33 (0.94–1.88) | 0.115  |
| >500 and ≤2000                                          | 2.25 (1.61–3.15) | <0.001  | 2.03 (1.41–2.91) | <0.001  |
| >2000                                                   | 5.1 (3.51–7.39) | <0.001  | 4.92 (3.29–7.36) | <0.001  |
| All-cause mortality‡                                      |
|                                                        |
| Normal D-dimer (<230 ng/mL)                              | 1.0  | 1.0  |
| Elevated D-dimer (≥230 ng/mL)                            | 3.54 (2.66–4.71) | <0.001  | 2.14 (1.56–2.92) | <0.001  |
| D-dimer level, ng/mL                                     |
| 230–500                                                  | 2.35 (1.73–3.2) | <0.001  | 1.66 (1.19–2.32) | <0.001  |
| >500 and ≤2000                                          | 4.26 (3.11–5.83) | <0.001  | 2.34 (1.65–3.31) | <0.001  |
| >2000                                                   | 7.69 (5.36–11.03) | <0.001  | 4.15 (2.79–6.18) | <0.001  |
| Discharged, no critical illness                          |
|                                                        |
| Normal D-dimer (<230 ng/mL)                              | 1.0  | 1.0  |
| Elevated D-dimer (≥230 ng/mL)                            | 0.31 (0.24–0.4) | <0.001  | 0.49 (0.37–0.65) | <0.001  |
| D-dimer level, ng/mL                                     |
| 230–500                                                  | 0.45 (0.34–0.6) | <0.001  | 0.63 (0.47–0.85) | <0.001  |
| >500 and ≤2000                                          | 0.26 (0.2–0.35) | <0.001  | 0.45 (0.33–0.61) | <0.001  |
| >2000                                                   | 0.14 (0.1–0.19) | <0.001  | 0.23 (0.18–0.34) | <0.001  |

ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; and OR, odds ratio.
*Odds ratios adjusted for age, sex, race, body mass index, tobacco use, hypertension, hyperlipidemia, chronic kidney disease, prior heart failure, atrial fibrillation, coronary artery disease, cancer, outpatient prescriptions for ACE or ARBs, anticoagulants, statin, β-blocker use, initial laboratory results for lymphocyte count, ferritin, and C-reactive protein.
†The breakdown of thrombosis is: all thrombosis, n=410; deep venous thrombosis, n=103; pulmonary embolism, n=68; myocardial infarction, n=208; ischemic stroke, n=37; systemic embolism, n=22.
‡Defined as death or transfer to inpatient hospice.
D-dimer can only be generated when there is formation and degradation of cross-linked fibrin, provides a global marker of activation of the coagulation and fibrinolysis, and is therefore reflective of enhanced thrombotic activity. In fact, several pathological reports demonstrate massive amounts of micro and macro thrombi in multiple vascular beds in COVID-19. There is also evidence to suggest that D-dimer may not only be a marker of hypercoagulability and a prothrombotic state but may participate in pathogenesis. Fibrin degradation products induce acute pulmonary dysfunction and have a direct procoagulant effect. Infusion of purified human fragment D into rabbits induces pulmonary capillary leakage and hypoxemia. Fragment D also increases platelet aggregation and prostaglandin synthesis, activates complement, and induces chemotaxis of neutrophils.

Our results boost the scientific rationale for clinical trials to reduce thrombotic risk and adverse outcomes. Patients with COVID-19 are at heightened risk for both arterial and venous thrombotic events. Cohort studies suggest that the incidence of thromboembolic complications in patients with COVID-19 ranges from 11% to 35%. A retrospective study done in China that included 449 hospitalized critically ill COVID-19 patients showed a lower mortality in patients who received prophylactic heparin >7 days than in patients not receiving anticoagulant treatment. Based on the limited data available, the International Society of Thrombosis and Hemostasis recommends a universal strategy of routine prophylactic dosed anticoagulation with unfractionated heparin or low-molecular weight heparin, after careful assessment of bleeding risk. A retrospective analysis of 2773 hospitalized patients with COVID-19 found no benefit of high-dose anticoagulation; however, a subgroup analysis in subjects treated with mechanical ventilation suggested...
a potential benefit with high-dose anticoagulation.\textsuperscript{31} Of note, patients infected with COVID-19 treated with anticoagulation are experiencing significant bleeding complications as well.\textsuperscript{32} The optimal strategy to prevent adverse clinical events is being studied in the ACTIV-4 (Accelerating COVID-19 Therapeutic Interventions and Vaccines-4) Antithrombotic Trial (URL: http://www.clinicaltrials.gov). Unique identifier: NCT04359277) among hospitalized patients with COVID-19 with elevated D-dimer.

**Limitations**

D-dimer levels were not routinely collected in all individuals; patients without any D-dimer level collected were excluded, and patients with worsening disease may have had D-dimers checked more frequently. Nonetheless, 85\% of all subjects hospitalized had at least one D-dimer level measured, and associations between baseline D-dimer and outcomes were robust even after adjustment for demographics, clinical characteristics, baseline medications, and initial laboratory results. Moreover, a standardized admission laboratory protocol was only established about 2 weeks into the epidemic, resulting in missing D-dimer data for earlier patients, especially those who were less acutely ill. However, missing D-dimer was not associated with clinical events.\textsuperscript{1} Second, although critical illness, acute kidney injury, and mortality were objective end points, thrombotic events were based on diagnoses assigned by treating physicians and were not independently adjudicated. The impact of ascertainment bias or diagnostic suspicion bias is unknown. Third, it is possible that the observed associations between D-dimer and outcomes are confounded by yet-to-be-determined factors; however, we adjusted our analysis for established and novel risk factors. Furthermore, we found comparable and robust odds ratios in and across risk groups, including low and high cardiovascular risk groups. Finally, only in-hospital events were captured in this analysis. We did not assess the association between D-dimer and subsequent cardiovascular events after hospital discharge.

**Conclusions**

D-dimer levels were independently associated with a higher risk of critical illness, thrombosis, acute kidney injury, and all-cause mortality among patients with COVID-19, independent of previously identified risk factors. The present study provides additional support that COVID-19 is a coagulopathic condition with D-dimer representing a direct link between COVID-19 infection and adverse outcomes.

**ARTICLE INFORMATION**

Received June 11, 2020; accepted August 8, 2020.
embolism. Acad Emerg Med. 2010;17:589–597. doi: 10.1111/j.1533-2712.2010.00765.x

15. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7:e438–e440. doi: 10.1016/S2353-3026(20)30145-9

16. Shah S, Shah K, Patel SB, Patel FS, Osman M, Velagapudi P, Turagam MK, Lakireddy D, Garg J. Elevated D-Dimer Levels are Associated with Increased Risk of Mortality in COVID-19: A Systematic Review and Meta-Analysis. https://www.medrxiv.org/content/10.1101/2020.04.29.20085407v1. Accessed May 5, 2020.

17. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–847. doi: 10.1111/jth.14768

18. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3

19. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091.

20. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, et al. Pulmonary vascular endothelitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 2020;383:120–128.

21. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173:268–277. doi: 10.7326/M20-2003

22. Levin A, Warnock DG, Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C; Acute Kidney Injury Network Working Group. Improving outcomes from acute kidney injury: report of an initiative. Am J Kidney Dis. 2007;50:1–4. doi: 10.1053/j.ajkd.2007.05.008

23. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu Z, Shan H, Lei CL, Hui DSC, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoA2002032

24. McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2:e437–e445.

25. Menter T, Haslbauer JD, Nienhold R, Savic S, Hopper H, Deigendesch N, Frank S, Turek D, Willi N, Pargger H, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variagated findings in lungs and other organs suggesting vascular dysfunction [published online May 4, 2020]. Histopathology. doi: 10.1111/his.14134. https://onlinelibrary.wiley.com/doi/full/10.1111/his.14134.

26. Manwaring D, Curreli PW. Cellular mediation of respiratory distress syndrome induced by fragment D. Ann Chir Gynaecol. 1981;70:304–307.

27. Manwaring D, Curreli PW. Platelet and neutrophil sequestration after fragment D-induced respiratory distress. Circ Shock. 1982;9:75–80.

28. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094–1099.

29. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18:1023–1026.

30. Maatman TK, Jalali F, Feizpour C, Douglas A II, McGuire SP, Kinneman G, Hartwell JL, Maatman BT, Kreutz RP, Kapoor R, et al. Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019 [published online May 27, 2020]. Crit Care Med. doi: 10.1097/CCM.0000000000004466. https://journals.lww.com/ccmjournal/FullText/2020/09000/Routine_Venous_Thromboembo-lism_Prophylaxis_May_Be.33.aspx.

31. Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, Charney AW, Narula J, Fayad ZA, Bagiella E, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76:122–124. doi: 10.1016/j.jacc.2020.05.001

32. Dogra S, Jain R, Cao M, Bilaloglu S, Zagzag D, Hochman S, Lewis A, Melmed K, Hochman K, Horwitz L, et al. Hemorrhagic stroke and anticoagulation in COVID-19. J Stroke Cerebrovasc Dis. 2020;29:104984. doi: 10.1016/j.jstrokecerebrovasdis.2020.104984